Ads
related to: bortezomib and multiple myeloma- IKEMA Patient Profile
Potential SARCLISA Candidates
See Who May Be Appropriate
- IKEMA Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Contact a Representative
For Questions and Information
About SARCLISA
- IKEMA Patient Profile
Search results
Results From The WOW.Com Content Network
Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma. [4] This includes multiple myeloma in those who have and have not previously received treatment. [3] It is generally used together with other medications. [3] It is given by injection. [4]
Bortezomib (Velcade) was approved in 2003. This was the first proteasome inhibitor approved for use in the U.S. Its boron atom binds the catalytic site of the 26S proteasome. [20] Carfilzomib (Kyprolis) was approved by the FDA for relapsed and refractory multiple myeloma in 2012 . [21]
Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. [6] Often, no symptoms are noticed initially. [10] As it progresses, bone pain, anemia, renal insufficiency, and infections may occur. [10]
bortezomib Velcade is indicated for the front-line treatment of multiple myeloma and for patients with mantle cell lymphoma who have received at least 1 prior therapy. 05-13-2003 Ortho Biotech and Janssen-Cilag, members of the Johnson & Johnson Family of Companies, are responsible for commercialization of VELCADE in Europe and the rest of the ...
Bortezomib/dexamethasone is a combination drug against multiple myeloma. [1] When bortezomib is used by the trade name Velcade, the combination is called Vel/Dex (or Vel-Dex or Veldex). Bortezomib is a proteasome inhibitor and dexamethasone is a corticosteroid.
bortezomib, dexamethasone plus platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide: multiple myeloma: VIFUP vinorelbine, cisplatin, fluorouracil: locally advanced/metastatic breast cancer: VIP vinblastine, ifosfamide, platinum agent, (etoposide (VP-16) may substitute for vinblastine, making a regimen sometimes referred to as ...